首页 > 文献资料
-
大量环已亚硝脲与自身骨髓移植治疗小儿脑部恶性肿瘤
本文报道应用大剂量环已亚硝脲(CCNU)辅以自身骨髓移植治疗小儿脑肿瘤22例.分三组采用不同方案治疗,均能渡过药物所致骨髓抑制期,可以延长小儿脑部恶性肿瘤手术后的生存期,并有可能获得痊愈.
-
儿童脊柱结核早期诊断误诊原因分析(附184例报告)
我院小儿外科自1966年到1984年间收治儿童脊柱结核184例.本文仅就误诊原因、早期诊断以及治疗效果的关系报告如下:
-
表面加强解析电离-飞行时间-质谱仪检测大鼠肾脏缺血再灌注早期血清蛋白质谱变化
肾脏缺血再灌注(I/R)损伤是导致急性肾衰竭(ARF)主要的因为,但到目前为止,仍没有一项比较实用可行的指标诊断早期缺血性急性肾衰竭~([1,2]).我们应用表面加强解析电离-飞行时间-质谱仪(SELDI-TOF-MS)检测大鼠正常对照组与肾I/R组早期血清的蛋白质谱,筛选肾脏I/R后早期差异表达的标记蛋白质,为临床早期诊断急性肾衰竭寻找更为可靠的指标.
-
肾移植术后早期急性肾功能损害救治及存活率临床分析
肾移植受者南于急性排斥、急性肾小管坏死和尿路梗阻等特殊原因可造成移植肾急性肾功能损害(AKI),而且发生AKI的可能性远高于一般人群.移植后早期的基础肾功能对移植肾长期生存有重要的影响,所以AKI的救治成功与否成为影响移植肾长期生存率的突出问题[1].本研究总结奉中心50例术后早期发生移植肾AKI患者的疗效和人、肾长期存活率.
-
糖尿病肾病大鼠不同时期肾小球一氧化氮-血管内皮生长因子轴的变化特点
糖尿病肾病(DN)时肾小球内一氧化氮(NO)-内皮生长因子(VEGF)轴失衡,且可能对启动DN的发生发展发挥重要作用[1].但目前对DN的肾小球NO-VEGF轴失衡的原因尚不明确.本研究应用DN大鼠模型研究DN不同时期肾小球NO-VEGF轴失衡的原因和特点,探讨影响NO-VEGF轴变化的因素.
-
非小细胞肺癌患者ERCC1,β-tubulin Ⅲ的表达与TP/NP方案化疗敏感性关系分析
近20年来,随着第3代化疗新药(异长春花碱、紫杉类和吉西他滨等)在临床的广泛应用,以铂类为基础联合第3代化疗新药的方案已成为非小细胞肺癌(NSCLC)病人的标准化疗(SC)方案,但是化疗的反应率(RR)、总生存时间(OS)和肿瘤进展时间(TTP)仍然很低,而且不同NSCLC病人对同一种标准化疗方案疗效差异很大[1].
-
Application of Proteomics to Cancer Molecular Diagnostics
Strategies to achieve personalized medicine and improve public health encompass assessment of an individual's risk for disease, early detection and molecular classification of disease resulting in an informed choice of the most appropriate treatment instituted at an early stage of disease develop- ment. A major contribution of proteomics in this field is the development of blood based tests to achieve the goals of personalized medicine.
-
美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新
本文旨在为Ⅳ期非小细胞肺癌患者的治疗提供更新版推荐.本文资料检索源自2002年以来公布的相关随机试验文献.此指南范围限于化疗与生物治疗.更新委员会对这些文献进行了总结并提供了推荐更新.162篇文献符合标准被纳入参考.本推荐基于可改善总生存期的治疗方法.仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测.对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用.对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合.对于体力状态评分为2分的患者,单一细胞毒性药物即可.对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗.即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗.对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳.除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用.对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用.多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗.对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗.现有数据不足以推荐常规三线采用细胞毒性药物.已有的证据也不足以推荐常规应用分子标记物选择化疗.
-
The New Lung Cancer Staging System
The International Association for the Study of Lung Cancer (IASLC) has conducted an extensive initiative to inform the revision of the lung cancer staging system. This involved development of an international database along with extensive analysis of a large population of patients and their prognoses. This article reviews the recommendations of the IASLC International Staging Committee for the definitions for the TNM descriptors and the stage grouping in the new non-small cell lung cancer staging system.
-
腹腔镜在腹膜透析置管术后漂移堵塞再置管的处理体会
腹膜透析目前作为终末期肾脏疾病(end stage renaldisease,ESRD)重要的替代治疗方法之一,在临床上已得到广泛应用.传统的置管术是采用局部或硬膜外麻醉在腹壁做一切口,但经这一切口不能观察腹腔的情况,难以目视确定导管放置的正确位置,术后部分患者的导管容易发生移位,而常规方法不易纠正移位的导管位置,或因大网膜堵塞导管造成堵管不能再通时常须拔管后再置管.
-
高通量血液透析临床研究进展
血液透析( hemodialysis,HD)作为终末期肾脏病(end- stage renal disease,ESRD)肾替代治疗的一种重要手段,极大提高了透析患者生存率.近年来随着人工合成膜的快速发展,随着血液透析模式的不断更新,高通量血液透析(high - fluxhemo - dialysis,HFHD)因其良好的生物相容性和对中大分子尿毒症毒素的清除,成为血液净化领域一种新兴的高效血液净化方法,应用日趋广泛.
-
颅脑创伤康复期应用计算机通讯促进恢复的研究进展
电子邮件通讯技术已经广泛被应用于颅脑创伤多中心医师之间、医师对患者及其家属问卷调查等研究之中,诸如利用电子邮件调查工具进行颅脑创伤患者输血指征调杳、康复治疗期间颅脑创伤深静脉血栓形成、肺栓塞形成的筛查、预防、治疗的多中心研究.
-
脑损伤急性期丘脑-垂体-肾上腺轴损害与应激障碍的临床意义
创伤性脑损伤(traumatic brain injury,TBI)以其高发病率、高死亡率及高致残率己成为影响人民健康的重大疾病之一~([1-3]).
-
BACKGROUND:?Combined? hepatocellular? carcinoma? and?cholangiocarcinoma?(cHCC-CC)?is?a?rare?subtype?of?primary?liver?cancer?consisting?of?both?hepatocellular?carcinoma?(HCC)?and?cholangiocarcinoma?(CC).?Because?of?the?rarity?of?this?tumor,?its?feature?is?poorly?understood.?The?present?study?aimed?to?evaluate?the?clinicopathological?features?and?long-term?prognosis?of?patients?with?cHCC-CC?after?surgery?and?to?compare?with?those?of?the?patients?with?stage-matched?HCC?and?CC.METHODS:?The?clinicopathological?features?of?the?patients?who?underwent?surgery?for?cHCC-CC?at?our?center?during?the?period?of?2001-2010?were?retrospectively?analyzed?and?compared?with?those?of?stage-matched?HCC?and?CC?patients.?Cancer?staging?was?performed?according?to?the?AJCC Cancer Staging Manual?(6th?ed.).?Overall?survival?and?disease-free?survival?were?compared?among?the?groups?and?prognostic?factors?of?cHCC-CC?were?evaluated. RESULTS:?Signiifcant? differences? were? observed? in? clinico-pathological?features?among?42?patients?with?cHCC-CC,?90?patients?with?HCC?and?45?patients?with?CC.?Similar?to?HCC?patients,?cHCC-CC?patients?had?frequent?hepatitis?B?virus?antigen?positivity,?microscopic?vessel?invasion,?cirrhosis?and?high?level?of?serum?alpha-fetoprotein.?Similar?to?CC?patients,?cHCC-CC?patients?showed?increased?bile?duct?invasion?and?decreased?capsule.?The?1-,?3-,?and?5-year?overall?survival?and?disease-free?survival?of?patients?with?cHCC-CC?were?not?signiifcantly?different?from?those?with?stage-matched?patients?with?CC; but?signiifcantly?poorer?than?those?with?HCC.?In?subanalysis?of?patients?with?stage?II,?the?overall?survival?in?patients?with?cHCC-CC?or?CC?was?signiifcantly?poorer?than?that?in?patients?with?HCC.?We?did?not?ifnd?the?difference?in?patients?with?other?stages.?Univariate?analysis?of?overall?and?disease-free?survival?of?patients?with?cHCC-CC?showed?that?the?vascular?invasion?and?intrahepatic?metastasis?were?the?signiifcant?predictive?factors. CONCLUSION:?Patients?with?cHCC-CC?showed?similar?clinico-pathological?features?as?those?with?HCC?or?CC,?and?patients?with?cHCC-CC?or?CC?had?a?poorer?prognosis?compared?with?those?with?HCC,?especially?at?matched?stage?II.